Sona Nanotech’s Breakthrough in Cancer Treatment Study
Company Announcements

Sona Nanotech’s Breakthrough in Cancer Treatment Study

Sona Nanotech, Inc (TSE:SONA) has released an update.

Sona Nanotech Inc. reports remarkable interim results from its Dalhousie University study, showing an 80% reduction in tumor size from a single Targeted Hyperthermia Therapy treatment using its gold nanorods. Additionally, the company’s latest batch of polymer-coated gold nanorods has shown improved physical uniformity and purity, potentially leading to cost reductions in scaled manufacturing. These advancements may support future regulatory applications and enhance the company’s position in the nanomedicine field.

For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskSona Nanotech’s Therapy Shows Lasting Anti-Cancer Immunity
TipRanks Canadian Auto-Generated NewsdeskSona Nanotech’s Therapy Excels in Melanoma Trials
TipRanks Canadian Auto-Generated NewsdeskSona Nanotech Welcomes New CMO, Advances Patent Filing
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!